Literature DB >> 13129705

Intracellular antibodies and challenges facing their use as therapeutic agents.

M Natividad Lobato1, Terence H Rabbitts.   

Abstract

A key feature of antibodies is their ability to bind antigens with high specificity and affinity. This has led to the concept of intracellular antibodies (intrabodies), designed to mimic antibody-antigen binding, but inside cells. Antibody fragments comprising the antigen-binding variable domains are convenient formats for intrabodies, potentially allowing for intracellular functionality. Intrabodies are promising tools, capable of interfering with a wide range of molecular targets in various intracellular compartments. However, many significant challenges remain to be overcome before intrabodies can be useful therapeutic agents. Although major progress has been made in the design and selection of intrabodies, new developments and advances are needed to allow their efficient delivery and expression for treatment of human diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13129705     DOI: 10.1016/s1471-4914(03)00163-1

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  24 in total

Review 1.  Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins.

Authors:  David C Butler; Julie A McLear; Anne Messer
Journal:  Prog Neurobiol       Date:  2011-11-18       Impact factor: 11.685

Review 2.  Antibody-enabled small-molecule drug discovery.

Authors:  Alastair D G Lawson
Journal:  Nat Rev Drug Discov       Date:  2012-06-29       Impact factor: 84.694

3.  Protocol for the selection of single-domain antibody fragments by third generation intracellular antibody capture.

Authors:  Tomoyuki Tanaka; Terence H Rabbitts
Journal:  Nat Protoc       Date:  2009-12-17       Impact factor: 13.491

4.  Generating differentially targeted amyloid-beta specific intrabodies as a passive vaccination strategy for Alzheimer's disease.

Authors:  Kelly L Sudol; Michael A Mastrangelo; Wade C Narrow; Maria E Frazer; Yona R Levites; Todd E Golde; Howard J Federoff; William J Bowers
Journal:  Mol Ther       Date:  2009-07-28       Impact factor: 11.454

5.  Intrabody expression in eukaryotic cells.

Authors:  Laurence Guglielmi; Pierre Martineau
Journal:  Methods Mol Biol       Date:  2009

6.  Monitoring cotranslational protein folding in mammalian cells at codon resolution.

Authors:  Yan Han; Alexandre David; Botao Liu; Javier G Magadán; Jack R Bennink; Jonathan W Yewdell; Shu-Bing Qian
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-16       Impact factor: 11.205

7.  Immunosympathectomy as the first phenotypic knockout with antibodies.

Authors:  Antonino Cattaneo
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-20       Impact factor: 11.205

8.  EMMPRIN reduction via scFv-M6-1B9 intrabody affects α3β1-integrin and MCT1 functions and results in suppression of progressive phenotype in the colorectal cancer cell line Caco-2.

Authors:  S Sangboonruang; P Thammasit; N Intasai; W Kasinrerk; C Tayapiwatana; K Tragoolpua
Journal:  Cancer Gene Ther       Date:  2014-06-13       Impact factor: 5.987

Review 9.  Contributions of immunoaffinity chromatography to deep proteome profiling of human biofluids.

Authors:  Chaochao Wu; Jicheng Duan; Tao Liu; Richard D Smith; Wei-Jun Qian
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-01-12       Impact factor: 3.205

10.  Loss-of-function screening by randomized intracellular antibodies: identification of hnRNP-K as a potential target for metastasis.

Authors:  Atsushi Inoue; Shinya Y Sawata; Kazunari Taira; Renu Wadhwa
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.